The Authors: Roslyn Francis, MBBS PhD, is Associate Professor of Molecular Imaging UWA with a clinical position in the Department of Nuclear Medicine/WA PET Service at Sir Charles Gairdner Hospital (SCGH). She performs research in novel molecular imaging agents, with a particular interest in mesothelioma. Tatiana Segard, MD, is a Clinical Research Fellow, with experience in hypoxia imaging agents. Laurence Morandeau, PhD, is a Research Radiochemist at the Radiopharmaceutical and Development (RAPID) laboratory, SCGH. Laurence has been responsible for the synthesis development and quality control of novel PET agents for clinical use.
Novel molecular imaging in lung and pleural diseases
Article first published online: 27 OCT 2011
© 2011 The Authors. Respirology © 2011 Asian Pacific Society of Respirology
Volume 16, Issue 8, pages 1173–1188, November 2011
How to Cite
FRANCIS, R., SEGARD, T. and MORANDEAU, L. (2011), Novel molecular imaging in lung and pleural diseases. Respirology, 16: 1173–1188. doi: 10.1111/j.1440-1843.2011.02059.x
SERIES EDITOR: DARRYL KNIGHT
- Issue published online: 27 OCT 2011
- Article first published online: 27 OCT 2011
- Accepted manuscript online: 6 SEP 2011 12:23PM EST
- Received 14 April 2011; invited to revise 9 June 2011; revised 1 August 2011; accepted 20 August 2011.
- molecular imaging;
- positron emission tomography;
- thoracic neoplasm
Molecular imaging provides an opportunity to study biological processes in vivo. Specific molecular ‘probes’ are labelled with radioactive tracers, and imaging is carried out using either PET or gamma-cameras. The imaging is quantitative, and therefore the activity of a specific biological process (e.g. metabolism or proliferation) can be numerically assessed, which may be important for prognosis or therapy monitoring. The use of molecular imaging may lead to the development of a ‘molecular profile’ of a disease, therefore facilitating individualization of therapy and rational treatment approaches. This review article summarizes the most commonly used molecular imaging agents and their role in lung and pleural diseases. This is a rapidly developing field as new targets and imaging probes are being developed and as their clinical roles are being established.